Using clinical big data and multi-omics data, including proteomics and metabolomics techniques, Li explored the epidemiology of NAFLD and the mechanism of its progression to NASH. “We discovered ...
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...
Hosted on MSN17d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseasesAbout 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...
20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer. Is it time to increase your chances of clinical success with a new human-relevant ...
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...
but untreated disease can progress to severe conditions such as non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer.” Although no specific drugs are approved yet for treating NAFLD ...
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback